Chronic myelogenous leukemia following repeated radiation therapy for histiocytosis X.
Low dose radiotherapy has been used to treat a variety of benign disorders including Histiocytosis X. Ionizing radiation may be leukemogenic with leukemia developing between 3.5 to 11 years after exposure. Twenty to 30% of these leukemias are chronic myelogenous leukemia (CML). In this report the rare development of PH1 + CML 11 years after radiation therapy for Histiocytosis X is recorded.
Chap
L
L
Department of Medicine, UCLA School of Medicine.
Nimer
S D
SD
D000328:Adult; D001918:Brachytherapy / Q000009:adverse effects*; D002874:Chromosome Mapping; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D005260:Female; D005500:Follow-Up Studies; D006646:Histiocytosis, Langerhans-Cell / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology* / Q000235:genetics / Q000628:therapy; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000628:therapy; D009689:Nuclear Warfare; D010677:Philadelphia Chromosome; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000532:radiotherapy; D013997:Time Factors; D014178:Translocation, Genetic; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy
D007457:Iodine Radioisotopes